LONDON--(BUSINESS WIRE)--Technavio has announced their latest pipeline analysis report on the drug pipeline for laryngeal cancer. The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat laryngeal cancer.
This report by Technavio presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market.
This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing
Laryngeal cancer: Market overview
Laryngeal cancer, which is also known as larynx cancer, is a type of head and neck cancer where tumor cells are formed in the tissue of the larynx. The larynx is a part of the throat and is situated between tongue and trachea. It contains vocal cords, which are responsible for manipulation of pitch and volume of speech and are required for phonation. It is also known as the voice box.
According to a senior market research analyst at Technavio, “Larynx cancer is caused due to smoking, eating tobacco, and drinking excessive alcohol. It can also be caused due to human papillomavirus. Conditions such as poor diet, low immunity, and family history may also cause larynx cancer. Exposure to some chemicals such as formaldehyde, nickel, isopropyl alcohol, sulfuric acid mist, and diesel fumes can also lead to this disease. Moreover, regular exposure to high level of wood dust, coal dust, paint fumes, and coal as a fuel source can result in laryngeal cancer.”
Laryngeal cancer: Segmentation analysis
This pipeline analysis report segments the laryngeal cancer market based on therapies employed (monotherapy and combination therapy), RoA (oral), therapeutic modality (small molecule, monoclonal antibody, and biological), targets (EGFR, ETBR, HER2, immune system, PI3K, PARP, protein synthesis, tumor cells, and WEE1 kinase), MoA (EGFR inhibitor, ETBR antagonists, HER2 inhibitor, immunomodulator, PI3K inhibitor, PARP inhibitors, protein synthesis inhibitors, and WEE1 kinase inhibitor), geographical segmentation (US, UK, and The Netherlands) and recruitment status (active, not recruiting, and recruiting). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.
Based on therapeutic modality, more than 60% of the molecules that are being investigated for the treatment of laryngeal cancer are small molecules.
Looking for more information on this market? Request a free sample report
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Scope of the Report
Regulatory Framework
Drug Development Landscape
- Drugs under development
- Indications coverage
Drug Development Strategies
- Therapies employed
- RoA
- Therapeutic modality
- Geographical coverage
Recruitment Strategies
- Recruitment status
- Gender
- Age
Key Companies
- Type of players
- Company overview
Discontinued or Dormant Molecules
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at media@technavio.com.
